NCT01836133View on ClinicalTrials.gov

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

Erlotinib 150 mg

Trial Locations (5)

11000

Clinical Center of Serbia; Institute For Pulmology, Belgrade

Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade

Military Medical Academy; Clinic for Pulmonology, Belgrade

18000

Clinical Center Nis; Clinic for pulmonary diseases Knez Selo, Knez-Selo

21204

Institute for pulmonary diseases of Vojvodina, Kamenitz

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01836133 - An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) | Biotech Hunter | Biotech Hunter